2024
HIV and Substance Use Disorders
Lier A, Tarfa A, Shenoi S, Kuo I, Springer S. HIV and Substance Use Disorders. Infectious Disease Clinics Of North America 2024, 38: 599-611. PMID: 38960783, PMCID: PMC11410345, DOI: 10.1016/j.idc.2024.06.003.Peer-Reviewed Original ResearchHuman immunodeficiency virusSubstance use disordersEvidence-based public health effortsHuman immunodeficiency virus acquisitionHuman immunodeficiency virus incidenceRisk of HIV acquisitionUntreated substance use disordersPoor HIV outcomesAdherence to HIV antiretroviral therapyHIV antiretroviral therapyPublic health effortsInjection drug useAntiretroviral therapyHIV acquisitionImmunodeficiency virusHIV outcomesHealth effortsTreatment strategiesIncreased riskDrug useSubstance useDrugAmericanRiskPersonsPerspectives on benefits and risks of creation of an “injection drug use” billing code
Sundaram G, Sato T, Goodman-Meza D, Haddad M, Thakarar K, Feinberg J, Springer S, Barton K, Butler N, Eaton E, Wurcel A. Perspectives on benefits and risks of creation of an “injection drug use” billing code. Journal Of Substance Use And Addiction Treatment 2024, 164: 209392. PMID: 38735482, DOI: 10.1016/j.josat.2024.209392.Peer-Reviewed Original ResearchInjection drug useSubstance use disordersInternational Classification of DiseasesIncreased riskICD-10 codesDrug useClassification of DiseasesHealthcare utilizationHealth servicesIncreased risk of overdoseFinancial reimbursementInternational ClassificationHealthcare systemRisk of overdoseTreatment servicesICD codesIdentifying peopleWell-beingPWIDUse disorderSystem of resource allocationHealthRiskImproved systemPotential benefitsHIV Risk and Interest in Preexposure Prophylaxis in Justice-Involved Persons - Volume 30, Supplement—March 2024 - Emerging Infectious Diseases journal - CDC
Nijhawan A, Pulitzer Z, Torres B, Noreen N, Schultheis A, Frank C, Colon R, Brooks R, Proffitt R, Pankow J, Bennett A, Salyards M, Kuo I, Knight K, Springer S. HIV Risk and Interest in Preexposure Prophylaxis in Justice-Involved Persons - Volume 30, Supplement—March 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: s68-s74. PMID: 38561803, PMCID: PMC10986824, DOI: 10.3201/eid3013.230739.Peer-Reviewed Original ResearchConceptsHIV riskAssess HIV risk factorsPreexposure prophylaxisPartners of unknown HIV statusMobile health unitReport injection drug useUnknown HIV statusPerceived HIV riskRisk factorsHIV risk factorsRandomized controlled trialsPatient navigationPrEP indicationsInjection drug useHealth unitsJustice-involved personsHIV medicationsHIV statusCondomless sexPrEPEducational effortsDrug useHIVRiskPersons
2020
Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam.
Wagman JA, Wynn A, Matsuzaki M, Gnatienko N, Metsch LR, Del Rio C, Feaster DJ, Nance RM, Whitney BM, Delaney JAC, Kahana SY, Crane HM, Chandler RK, Elliott JC, Altice F, Lucas GM, Mehta SH, Hirsch-Moverman Y, El-Sadr WM, Vu Q, Nguyen Thanh B, Springer SA, Tsui JI, Samet JH. Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam. AIDS 2020, 34: 2285-2294. PMID: 33048870, PMCID: PMC7951611, DOI: 10.1097/qad.0000000000002716.Peer-Reviewed Original ResearchConceptsHazardous alcohol useFormer injection drug useART receiptViral suppressionInjection drug useLow-middle income countriesAlcohol useAntiretroviral therapyMiddle-income countriesDrug useAlcohol Use Disorders Identification Test (AUDIT) scoresHIV viral suppressionAlcohol Use Disorders Identification TestDisorders Identification TestTherapy receiptHIV continuumMean ageHigh-income countriesCare outcomesLogistic regressionUpper middle-income countriesPLHIVDrugsIdentification TestHIVFederal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA’s Advocacy Agenda
Springer SA, Barocas J, Wurcel A, Nijhawan A, Thakarar K, Lynfield R, Hurley H, Snowden J, Thornton A, del Rio C. Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA’s Advocacy Agenda. The Journal Of Infectious Diseases 2020, 222: s230-s238. PMID: 32877568, PMCID: PMC7467230, DOI: 10.1093/infdis/jiz673.Peer-Reviewed Original ResearchMeSH KeywordsBacteremiaCommunicable Disease ControlFederal GovernmentHealth PolicyHepatitis BHepatitis CHIV InfectionsHuman RightsHumansIllicit DrugsInfectious Disease MedicineIntersectoral CollaborationInvasive Fungal InfectionsOpioid EpidemicPatient AdvocacyPreventive Health ServicesPublic Health AdministrationSocieties, MedicalState GovernmentSubstance-Related DisordersUnited StatesConceptsIllicit drug useInfectious diseasesAddiction specialistsDrug useSubstance use disorder treatmentUse disorder treatmentHarm reduction toolHIV physiciansInfectious complicationsEvidence-based practiceHIV epidemicOpioid epidemicCare continuumAssociated InfectionsTreatment servicesDisorder treatmentOpioid crisisDiseaseIDSAReview programEpidemicFurther disseminationHuman rights-based responseAdvocacy agendaMorbidity
2019
Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes
Makarenko I, Pykalo I, Springer SA, Mazhnaya A, Marcus R, Filippovich S, Dvoriak S, Altice FL. Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes. Journal Of Substance Use And Addiction Treatment 2019, 104: 34-41. PMID: 31370983, PMCID: PMC8215516, DOI: 10.1016/j.jsat.2019.05.008.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid agonist treatmentXR-NTX injectionXR-NTX treatmentXR-NTXUrine drug testingOpioid useExtended-release naltrexoneMonths of treatmentThree-month outcomeHealth-related qualityAdverse side effectsSymptoms of depressionOpioid dependenceAgonist treatmentLife scoresTreatment optionsIndependent factorsSide effectsUse disordersPeriod of observationDrug useStimulant useTreatment motivationDrug testingImpact of Abstinence and of Reducing Illicit Drug Use Without Abstinence on Human Immunodeficiency Virus Viral Load
Nance RM, Trejo MEP, Whitney BM, Delaney JAC, Altice F, Beckwith CG, Chander G, Chandler R, Christopoulous K, Cunningham C, Cunningham WE, Del Rio C, Donovan D, Eron JJ, Fredericksen RJ, Kahana S, Kitahata MM, Kronmal R, Kuo I, Kurth A, Mathews WC, Mayer KH, Moore RD, Mugavero MJ, Ouellet LJ, Quan VM, Saag MS, Simoni JM, Springer S, Strand L, Taxman F, Young JD, Crane HM. Impact of Abstinence and of Reducing Illicit Drug Use Without Abstinence on Human Immunodeficiency Virus Viral Load. Clinical Infectious Diseases 2019, 70: 867-874. PMID: 30994900, PMCID: PMC7319266, DOI: 10.1093/cid/ciz299.Peer-Reviewed Original ResearchConceptsMethamphetamine/crystalViral suppressionViral loadIllicit opioidsIllicit drug useDrug useRelative viral loadHuman immunodeficiency virus (HIV) viral loadNumber of PLWHSubstance useHIV viral loadHuman immunodeficiency virusLongitudinal cohort studyHarm reduction interventionsCrystal useCocaine/crackHIV clinicCohort studyVL suppressionImmunodeficiency virusImpact of abstinenceClinical studiesHigher oddsDrug categoriesOpioids
2012
Post-Release Substance Abuse Outcomes Among HIV-Infected Jail Detainees: Results from a Multisite Study
Krishnan A, Wickersham JA, Chitsaz E, Springer SA, Jordan AO, Zaller N, Altice FL. Post-Release Substance Abuse Outcomes Among HIV-Infected Jail Detainees: Results from a Multisite Study. AIDS And Behavior 2012, 17: 171-180. PMID: 23142854, PMCID: PMC3600070, DOI: 10.1007/s10461-012-0362-3.Peer-Reviewed Original ResearchMeSH KeywordsAdultBehavior, AddictiveFemaleHealth Services AccessibilityHealth Services Needs and DemandHIV InfectionsHumansIll-Housed PersonsInsurance, HealthMaleMiddle AgedMultivariate AnalysisPatient DischargePrevalencePrisonsProspective StudiesSeverity of Illness IndexSocial WorkSocioeconomic FactorsSubstance-Related DisordersTreatment OutcomeYoung AdultConceptsOpioid useJail detaineesPoor health outcomesSubstance use disordersSubstance abuse outcomesSubsequent drug useSubstance abuse treatmentOpioid relapseProspective cohortPsychiatric morbidityAppropriate diagnosisHigh prevalenceComplicate treatmentPsychiatric careUse disordersAlcohol severitySix monthsHealth outcomesDrug useHIVHealthcare accessAbuse treatmentSubstance abuseDrug relapseHealthcare outcomes
2011
HIV-Related Research in Correctional Populations: Now is the Time
Rich JD, Wohl DA, Beckwith CG, Spaulding AC, Lepp NE, Baillargeon J, Gardner A, Avery A, Altice FL, Springer S, On behalf of the Centers for AIDS Research—Collaboration on HIV in Corrections (CFAR-CHIC) Working Group. HIV-Related Research in Correctional Populations: Now is the Time. Current HIV/AIDS Reports 2011, 8: 288. PMID: 21904902, PMCID: PMC3208731, DOI: 10.1007/s11904-011-0095-3.Peer-Reviewed Original ResearchConceptsPrevention of HIVTransmission of HIVMental health disordersAcademic medical centerIllicit drug useEpidemic of incarcerationHIV-Related ResearchAntiretroviral therapyHIV infectionHIV transmissionMedical CenterHIVHealth disordersDrug useRisk behaviorsAIDS researchSubstance useSubstantial proportionNational InstituteRecent evidenceIncarcerated populationsPublic healthHealthCorrectional populationsPopulation
2009
Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy
Springer SA, Chen S, Altice F. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care 2009, 21: 976-983. PMID: 20024753, PMCID: PMC2797133, DOI: 10.1080/09540120802657555.Peer-Reviewed Original ResearchConceptsInjection drug usersCES-D scoresMajor depressive disorderAntiretroviral therapyCD4 countDepressive symptomsDrug usersDrug useHIV-1 RNA levelsProspective clinical trialsSubstance abuse treatment servicesSelf-administered therapyActive drug useNon-Caucasian raceSix-month followSix-month dataAntidepressant medicationAntiretroviral treatmentPoor adherenceSymptomatic responseMale genderClinical trialsDepressive disorderDepression ScaleDrug treatment
2008
A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners.
Springer SA, Bruce RD. A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners. Journal Of Opioid Management 2008, 4: 81-6. PMID: 18557164, PMCID: PMC2476214, DOI: 10.5055/jom.2008.0012.Peer-Reviewed Original ResearchConceptsOpioid substitution therapySubstitution therapyAntiretroviral medicationsHIV riskDrug useOpioid-dependent prisonersConnecticut DepartmentPatient care capacityMaintenance therapyOpioid dependencyBUP treatmentTherapyReferral programBuprenorphineLess adherenceHIVMethadoneMinority of respondentsMajority of inmatesPilot studyAnonymous surveyMedicationsMore educationResults of answersAdherence